Myelodysplastic syndromes - The epigenetic model for drug development?

Research output: Contribution to journalEditorialpeer-review


Application of sequencing technology has advanced our understanding of the molecular landscape of myelodysplastic syndromes (MDS). Recurrent driver mutations in genes implicated in epigenetic regulation, and functional modelling of the disease has proven the importance of epigenetic dysregulation in MDS pathogenesis. Although available therapies such as azacitidine and decitabine are thought to exert their effect by epigenetic modulation, deep understanding of disease biology and development of specific epigenetically targeted therapies is still an area under active research. In this editorial we will focus on the molecular basis of MDS with particular focus on epigenetic dysregulation and new agents under development targeting this group of biological processes.

Original languageEnglish (US)
Pages (from-to)13-14
Number of pages2
JournalEuropean Oncology and Haematology
Issue number1
StatePublished - Jun 1 2016


  • Epigenetics
  • MDS
  • Myelodysplastic syndromes
  • Targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Myelodysplastic syndromes - The epigenetic model for drug development?'. Together they form a unique fingerprint.

Cite this